Skip to main content

Table 2 Main results of pooled ORs in this meta-analysis

From: Association of XPD Lys751Gln polymorphism with head and neck cancer susceptibility: evidence from 11,443 subjects

Study groups

n

Gln v Lys

Gln/Gln v Lys/Lys

Lys/Gln v Lys/Lys

Lys/Gln + Gln/Gln v Lys/Lys

Gln/Gln v Lys/Lys + Lys/Gln

  

OR (95% CI)

Ph

OR (95% CI)

Ph

OR (95% CI)

Ph

OR (95% CI)

Ph

OR (95% CI)

Ph

All

18

1.05(0.95–1.18)

<0.001

1.18(0.96–1.45)

0.030

1.02(0.90–1.17)

0.011

1.05(0.91–1.21)

0.001

1.11(0.98–1.26)

0.359

Ethnicity

18

          

 Caucasian

11

1.08(0.96–1.23)

0.002

1.17(0.92–1.49)

0.008

1.06(0.91–1.25)

0.033

1.09(0.92–1.29)

0.004

1.11(0.97–1.27)

0.150

 Asian

7

0.99(0.78–1.26)

0.026

1.13(0.75–1.70)

0.437

0.95(0.73–1.23)

0.062

0.97(0.74–1.27)

0.028

1.09(0.74–1.60)

0.687

Source

           

 HB

13

1.11(0.98–1.27)

0.001

1.26(0.98–1.61)

0.014

1.07(0.91–1.27)

0.009

1.11(0.93–1.33)

0.001

1.16(1.00–1.33)

0.273

 Mix

1

1.05(0.88–1.26)

–

1.08(0.74–1.57)

–

1.08(0.83–1.41)

–

1.08(0.85–1.38)

–

1.04(0.73–1.47)

–

 PB

3

0.86(0.62–1.19)

0.193

1.25(0.44–3.54)

0.870

0.82(0.57–1.18)

0.181

0.83(0.57–1.19)

0.168

1.26(0.45–3.57)

0.888

 nest

1

0.78(0.56–1.08)

–

0.54(0.26–1.16)

–

0.90(0.56–1.46)

–

0.80(0.51–1.27)

–

0.58 (0.28–1.17)

–

Cancer type

6

0.95(0.72–1.25)

0.005

0.88(0.65–1.18)

0.185

0.87(0.60–1.27)

0.007

0.90(0.61–1.31)

0.002

0.97(0.73–1.28)

0.640

 LC

2

0.72(0.48–1.10)

0.339

0.72(0.48–1.10)

0.383

0.66(0.48–0.91)

0.347

0.69(0.48–0.97)

0.285

0.93(0.64–1.34)

0.655

 OC

3

1.16(0.68–1.98)

0.007

1.08(0.69–1.69)

0.075

1.18(0.67–2.05)

0.036

1.20(0.65–2.21)

0.012

1.02(0.66–1.58)

0.213

 NPC

1

0.60(0.36–1.00)

–

0.97(0.06–15.66)

–

0.54(0.31–0.94)

–

0.55(0.32–0.95)

–

1.10(0.07–17.72)

–

  1. Ph P-value of Q-test for heterogeneity test, HB hospital-based study, PB population-based study, nest nested case–control study, LC laryngeal cancer, OC oral cancer, NPC nasopharyngeal cancer.